JP2009502771A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009502771A5 JP2009502771A5 JP2008522091A JP2008522091A JP2009502771A5 JP 2009502771 A5 JP2009502771 A5 JP 2009502771A5 JP 2008522091 A JP2008522091 A JP 2008522091A JP 2008522091 A JP2008522091 A JP 2008522091A JP 2009502771 A5 JP2009502771 A5 JP 2009502771A5
- Authority
- JP
- Japan
- Prior art keywords
- bmp
- bone morphogenetic
- morphogenetic protein
- preparation
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 claims description 34
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 21
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 210000000130 stem cell Anatomy 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 230000011664 signaling Effects 0.000 claims description 11
- 230000001613 neoplastic effect Effects 0.000 claims description 10
- 102100021747 Leukemia inhibitory factor receptor Human genes 0.000 claims description 9
- 239000012190 activator Substances 0.000 claims description 8
- 230000004069 differentiation Effects 0.000 claims description 5
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims 13
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims 13
- 229940112869 bone morphogenetic protein Drugs 0.000 claims 13
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims 10
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims 10
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 claims 9
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 claims 9
- 108010064527 OSM-LIF Receptors Proteins 0.000 claims 7
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims 6
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims 6
- 108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 claims 4
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 claims 4
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 claims 4
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims 4
- 102100022545 Bone morphogenetic protein 8B Human genes 0.000 claims 4
- 101710117970 Bone morphogenetic protein 8B Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims 3
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 claims 2
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 claims 2
- 239000011324 bead Substances 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 102000045896 human BMP2 Human genes 0.000 claims 2
- 102000046148 human BMP4 Human genes 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- 101710142062 Leukemia inhibitory factor receptor Proteins 0.000 claims 1
- 101100165560 Mus musculus Bmp7 gene Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
- 230000002188 osteogenic effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000003439 radiotherapeutic effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 2
- 101001042362 Homo sapiens Leukemia inhibitory factor receptor Proteins 0.000 description 1
- 101100437777 Mus musculus Bmpr1a gene Proteins 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70085905P | 2005-07-19 | 2005-07-19 | |
| US60/700,859 | 2005-07-19 | ||
| PCT/IB2006/002296 WO2007010394A2 (en) | 2005-07-19 | 2006-07-19 | Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012044260A Division JP5891068B2 (ja) | 2005-07-19 | 2012-02-29 | Ｌｉｆおよびｂｍｐによる腫瘍性幹細胞の潜在的腫瘍形成能力の抑制 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009502771A JP2009502771A (ja) | 2009-01-29 |
| JP2009502771A5 true JP2009502771A5 (cg-RX-API-DMAC10.html) | 2012-04-19 |
| JP5189977B2 JP5189977B2 (ja) | 2013-04-24 |
Family
ID=37420973
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008522091A Expired - Lifetime JP5189977B2 (ja) | 2005-07-19 | 2006-07-19 | Ｌｉｆおよびｂｍｐによる腫瘍性幹細胞の潜在的腫瘍形成能力の抑制 |
| JP2012044260A Expired - Lifetime JP5891068B2 (ja) | 2005-07-19 | 2012-02-29 | Ｌｉｆおよびｂｍｐによる腫瘍性幹細胞の潜在的腫瘍形成能力の抑制 |
| JP2014262190A Withdrawn JP2015057452A (ja) | 2005-07-19 | 2014-12-25 | Ｌｉｆおよびｂｍｐによる腫瘍性幹細胞の潜在的腫瘍形成能力の抑制 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012044260A Expired - Lifetime JP5891068B2 (ja) | 2005-07-19 | 2012-02-29 | Ｌｉｆおよびｂｍｐによる腫瘍性幹細胞の潜在的腫瘍形成能力の抑制 |
| JP2014262190A Withdrawn JP2015057452A (ja) | 2005-07-19 | 2014-12-25 | Ｌｉｆおよびｂｍｐによる腫瘍性幹細胞の潜在的腫瘍形成能力の抑制 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9220756B2 (cg-RX-API-DMAC10.html) |
| EP (2) | EP3117833B1 (cg-RX-API-DMAC10.html) |
| JP (3) | JP5189977B2 (cg-RX-API-DMAC10.html) |
| KR (2) | KR101311061B1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU2006271308B2 (cg-RX-API-DMAC10.html) |
| CA (2) | CA2615491C (cg-RX-API-DMAC10.html) |
| DK (2) | DK3117833T3 (cg-RX-API-DMAC10.html) |
| ES (2) | ES2686093T3 (cg-RX-API-DMAC10.html) |
| HR (1) | HRP20181379T1 (cg-RX-API-DMAC10.html) |
| HU (2) | HUE042197T2 (cg-RX-API-DMAC10.html) |
| NZ (2) | NZ565172A (cg-RX-API-DMAC10.html) |
| PL (2) | PL3117833T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2007010394A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3117833T3 (en) * | 2005-07-19 | 2019-03-18 | Stemgen S P A | Inhibition of Tumor-rich Potential of Tumor Stem Cells with LIF |
| US8361955B2 (en) | 2008-02-13 | 2013-01-29 | Dkfz Deutsches Krebsforschungszentrum, Stiftung Des Offentlichen Rechts | Methods for treating and preventing brain tumors based on bone morphogenetic proteins |
| CA2995310A1 (en) | 2015-08-25 | 2017-03-02 | Histide Ag | Compounds for inducing tissue formation and uses thereof |
| EP3349778B1 (en) * | 2015-09-17 | 2021-09-01 | Histide AG | Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof |
| KR20180050744A (ko) * | 2015-09-17 | 2018-05-23 | 히스티드 아게 | 신생물성 세포를 비-신생물성 세포로 전환시키기 위한 약제학적 회합물 및 이것의 용도 |
| KR20180052705A (ko) * | 2015-09-17 | 2018-05-18 | 히스티드 아게 | 신생물성 세포를 비-신생물성 세포로 전환시키기 위한 약제학적 회합물 및 이것의 용도 |
| WO2017046226A2 (en) * | 2015-09-17 | 2017-03-23 | Histide Ag | Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof. |
| CA2998677A1 (en) * | 2015-09-17 | 2017-03-23 | Histide Ag | Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof |
| WO2020138503A1 (ja) * | 2018-12-28 | 2020-07-02 | 国立大学法人 東京大学 | 神経膠腫の治療および予防剤、脳腫瘍の悪性度のマーカーおよび脳腫瘍の予後マーカー、脳腫瘍の悪性度および予後の判定方法並びに腫瘍増殖を抑制する抗体 |
| WO2026022122A1 (en) * | 2024-07-23 | 2026-01-29 | Eos Research Sa | Checkpoint inhibitors in the treatment of glioblastoma multiforme |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5010175A (en) | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5324519A (en) * | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| GB9004890D0 (en) * | 1990-03-05 | 1990-05-02 | Heath John K | Leukaemia inhibitory factor |
| IE66205B1 (en) | 1990-06-14 | 1995-12-13 | Paul A Bartlett | Polypeptide analogs |
| US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
| CA2104576C (en) * | 1991-12-24 | 1997-04-15 | George Kannourakis | A method for the treatment of tumours and sarcomas |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
| US7592428B1 (en) * | 1992-11-17 | 2009-09-22 | Ludwig Institute For Cancer Research | Antibodies which bind specifically to activin receptor like kinases |
| US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
| US5593853A (en) | 1994-02-09 | 1997-01-14 | Martek Corporation | Generation and screening of synthetic drug libraries |
| US5539083A (en) | 1994-02-23 | 1996-07-23 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid combinatorial libraries and improved methods of synthesis |
| EP0756628B1 (en) * | 1994-04-29 | 2007-11-14 | Curis, Inc. | Morphogenic protein-specific cell surface receptors and uses therefor |
| US5525735A (en) | 1994-06-22 | 1996-06-11 | Affymax Technologies Nv | Methods for synthesizing diverse collections of pyrrolidine compounds |
| US5549974A (en) | 1994-06-23 | 1996-08-27 | Affymax Technologies Nv | Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof |
| US6281015B1 (en) * | 1994-12-16 | 2001-08-28 | Children's Medical Center Corp. | Localized delivery of factors enhancing survival of transplanted cells |
| US20010053371A1 (en) * | 1999-01-07 | 2001-12-20 | Waldemar Debinski | Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13 |
| US5804162A (en) | 1995-06-07 | 1998-09-08 | Alliance Pharmaceutical Corp. | Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5569588A (en) | 1995-08-09 | 1996-10-29 | The Regents Of The University Of California | Methods for drug screening |
| US6036920A (en) | 1996-05-09 | 2000-03-14 | 3-Dimensional Pharmaceuticals, Inc. | Microplate thermal shift assay apparatus for ligand development and multi-variable protein chemistry optimization |
| JP4892131B2 (ja) * | 1998-11-13 | 2012-03-07 | ストライカー コーポレイション | 癌の症状を緩和する方法 |
| EP1246617B1 (en) * | 1999-12-06 | 2006-09-13 | Rhode Island Hospital | Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of ovarian cancer |
| US20030162700A1 (en) * | 2000-03-03 | 2003-08-28 | Shipham Kylie Ann-Maree | Method of treatment |
| WO2005026382A1 (en) | 2003-09-12 | 2005-03-24 | Stemcell Technologies Inc. | Neural colony forming assay |
| JP2005098727A (ja) | 2003-09-22 | 2005-04-14 | Hosiden Corp | 振動センサ |
| CA2546465A1 (en) | 2003-12-05 | 2005-06-23 | The Board Of Trustees Of The Leland Stanford Junior University | Identification, isolation and elimination of cancer stem cells |
| EP2789342A1 (en) * | 2004-06-17 | 2014-10-15 | Thrasos Innovation, Inc. | TDF-related compounds and analogs thereof |
| DK3117833T3 (en) * | 2005-07-19 | 2019-03-18 | Stemgen S P A | Inhibition of Tumor-rich Potential of Tumor Stem Cells with LIF |
| ES2363358B1 (es) * | 2009-04-03 | 2012-06-21 | FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al | Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable. |
| EP2371860A1 (en) * | 2010-04-05 | 2011-10-05 | Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
| JO3421B1 (ar) | 2011-06-20 | 2019-10-20 | H Lundbeck As | طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية |
| WO2015050844A1 (en) * | 2013-10-01 | 2015-04-09 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancer with atovaquone-related compounds |
-
2006
- 2006-07-19 DK DK16171392.0T patent/DK3117833T3/en active
- 2006-07-19 WO PCT/IB2006/002296 patent/WO2007010394A2/en not_active Ceased
- 2006-07-19 CA CA2615491A patent/CA2615491C/en not_active Expired - Lifetime
- 2006-07-19 EP EP16171392.0A patent/EP3117833B1/en not_active Expired - Lifetime
- 2006-07-19 JP JP2008522091A patent/JP5189977B2/ja not_active Expired - Lifetime
- 2006-07-19 PL PL16171392T patent/PL3117833T3/pl unknown
- 2006-07-19 EP EP06795317.4A patent/EP1904093B1/en not_active Expired - Lifetime
- 2006-07-19 ES ES06795317.4T patent/ES2686093T3/es not_active Expired - Lifetime
- 2006-07-19 NZ NZ565172A patent/NZ565172A/xx unknown
- 2006-07-19 KR KR1020127028173A patent/KR101311061B1/ko not_active Expired - Lifetime
- 2006-07-19 DK DK06795317.4T patent/DK1904093T3/en active
- 2006-07-19 CA CA2790675A patent/CA2790675C/en not_active Expired - Lifetime
- 2006-07-19 HU HUE16171392A patent/HUE042197T2/hu unknown
- 2006-07-19 AU AU2006271308A patent/AU2006271308B2/en not_active Expired
- 2006-07-19 HU HUE06795317A patent/HUE040063T2/hu unknown
- 2006-07-19 ES ES16171392T patent/ES2710601T3/es not_active Expired - Lifetime
- 2006-07-19 PL PL06795317T patent/PL1904093T3/pl unknown
- 2006-07-19 US US11/996,214 patent/US9220756B2/en active Active
- 2006-07-19 NZ NZ598031A patent/NZ598031A/xx unknown
- 2006-07-19 HR HRP20181379TT patent/HRP20181379T1/hr unknown
- 2006-07-19 KR KR1020087003552A patent/KR101338533B1/ko not_active Expired - Lifetime
-
2012
- 2012-02-29 JP JP2012044260A patent/JP5891068B2/ja not_active Expired - Lifetime
-
2014
- 2014-12-25 JP JP2014262190A patent/JP2015057452A/ja not_active Withdrawn
-
2015
- 2015-11-16 US US14/942,157 patent/US9737589B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Bone vasculature and bone marrow vascular niches in health and disease | |
| Farkas et al. | Neuregulin-1 signaling is essential for nerve-dependent axolotl limb regeneration | |
| Kwon et al. | Articular cartilage tissue engineering: the role of signaling molecules | |
| Heese et al. | Neural stem cell migration toward gliomas in vitro | |
| Komitova et al. | Postischemic exercise attenuates whereas enriched environment has certain enhancing effects on lesion‐induced subventricular zone activation in the adult rat | |
| CA2169191C (en) | Neural regeneration using human bone morphogenetic proteins | |
| Bradbury et al. | NT‐3, but not BDNF, prevents atrophy and death of axotomized spinal cord projection neurons | |
| Golestaneh et al. | TGF-β, neuronal stem cells and glioblastoma | |
| Stocum | The role of peripheral nerves in urodele limb regeneration | |
| Pal et al. | Platelet-rich growth factor in oral and maxillofacial surgery | |
| Piccirillo et al. | Bone morphogenetic proteins regulate tumorigenicity in human glioblastoma stem cells | |
| Ara et al. | Bone morphogenetic proteins 4, 6, and 7 are up‐regulated in mouse spinal cord during experimental autoimmune encephalomyelitis | |
| O’Keeffe et al. | Effects of growth/differentiation factor 5 on the survival and morphology of embryonic rat midbrain dopaminergic neurones in vitro | |
| Mahay et al. | Growth factors in mesenchymal stem cells following glial‐cell differentiation | |
| Ahmad et al. | p75NTR is highly expressed in vestibular schwannomas and promotes cell survival by activating nuclear transcription factor κB | |
| Choi et al. | Enhanced osteogenesis by collagen‐binding peptide from bone sialoprotein in vitro and in vivo | |
| Liu et al. | Epigenetic regulation of NGF-mediated osteogenic differentiation in human dental mesenchymal stem cells | |
| JP2012107063A5 (cg-RX-API-DMAC10.html) | ||
| Lowery et al. | A survey of strategies to modulate the bone morphogenetic protein signaling pathway: current and future perspectives | |
| Bas et al. | Tgf β‐1 and Wnt signaling pathways collaboration associated with cochlear implantation Trauma‐Induced fibrosis | |
| Sullivan et al. | The role of growth/differentiation factor 5 (GDF5) in the induction and survival of midbrain dopaminergic neurones: relevance to Parkinson's disease treatment | |
| Hayashi et al. | Meningeal cells induce dopaminergic neurons from embryonic stem cells | |
| Wang et al. | Electroacupuncture induced spinal plasticity is linked to multiple gene expressions in dorsal root deafferented rats | |
| Storch et al. | Neural stem cells and Parkinson's disease | |
| Sherbet | Growth factors and their receptors in cell differentiation, cancer and cancer therapy |